Ascendis Pharma Endocrinology Division A/S: Financial statements 2020
CVR: 32323537
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Ascendis Pharma Endocrinology Division A/S (CVR 32323537) has filed annual accounts for 2020. In 2020, the company reported a gross profit of EUR -98,477,366 and a net result of EUR -107,518,319 compared with EUR -95,044,994 the year before. Equity in the 2020 report amounted to EUR -410,309,512.
- Gross Profit
- EUR -98,477,366
- Profit/Loss
- EUR -107,518,319
- Equity
- EUR -410,309,512
- Total Assets
- EUR 44,037,625
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -98.5M EUR | -107.5M EUR | -410.3M EUR | 0 |
| 2019 | - | -89.3M EUR | -95M EUR | -302.8M EUR | 0 |
| 2018 | - | -54.4M EUR | -59.2M EUR | -207.7M EUR | 0 |
| 2017 | - | -57.3M EUR | -60.3M EUR | -148.6M EUR | 0 |
| 2016 | - | -42.3M EUR | -44M EUR | -88.3M EUR | - |
Official annual report
How creditworthy is Ascendis Pharma Endocrinology Division A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2019. Gross profit came to DKK -89,300,964, and the net result was DKK -95,044,994.
About Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S and ACP 30.06.2012 2 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported revenue of EUR 140,817,000 and a net result of EUR -38,806,000 compared with EUR -121,118,000 the year before. Equity in the 2025 report amounted to EUR -935,650,000.
